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Background: Iron deficiency is a common problem in primary care and is usually treated with 
oral iron substitution. With the recent simplification of intravenous (IV) iron administration 
(ferric carboxymaltose) and its approval in many countries for iron deficiency, physicians may 
be inclined to overutilize it as a first-line substitution.
Objective: The aim of this study was to evaluate iron deficiency management and substitution 
practices in an academic primary care division 5 years after ferric carboxymaltose was approved 
for treatment of iron deficiency in Switzerland.
Methods: All patients treated for iron deficiency during March and April 2012 at the Geneva 
University Division of Primary Care were identified. Their medical files were analyzed for 
information, including initial ferritin value, reasons for the investigation of iron levels, suspected 
etiology, type of treatment initiated, and clinical and biological follow-up. Findings were assessed 
using an algorithm for iron deficiency management based on a literature review.
Results: Out of 1,671 patients, 93 were treated for iron deficiency. Median patients’ age was 
40 years and 92.5% (n=86) were female. The average ferritin value was 17.2 μg/L (standard 
deviation 13.3 μg/L). The reasons for the investigation of iron levels were documented in 82% 
and the suspected etiology for iron deficiency was reported in 67%. Seventy percent of the 
patients received oral treatment, 14% IV treatment, and 16% both. The reasons for IV treatment 
as first- and second-line treatment were reported in 57% and 95%, respectively. Clinical and 
biological follow-up was planned in less than two-thirds of the cases.
Conclusion: There was no clear overutilization of IV iron substitution. However, several steps 
of the iron deficiency management were not optimally documented, suggesting shortcuts in 
clinical reasoning.
Keywords: iron deficiency, iron substitution, general practice, quality of care, cross-sectional 
design
Introduction
Anemia is a global public health problem affecting both developing and developed 
countries. Overall, 24.8% of females and preschool children around the world suffer 
from anemia, and iron deficiency is considered to be among the most important con-
tributing factors.1 Iron deficiency without anemia affects 10%–30% of menstruating 
females in Europe and the US.2,3 Although prevalence of iron deficiency depends on 
age, sex, and socioeconomic status,4 it is a common problem in primary care and is an 
underrecognized cause of fatigue and other symptoms in females of childbearing age.5
Oral iron administration is the first-line therapy to manage the symptoms of iron 
deficiency and increase the ferritin value. However, oral administration presents 
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disadvantages, such as low absorption of iron and the high 
incidence of gastrointestinal side effects. In addition, it should 
be used with caution in patients with advanced renal failure 
or chronic heart failure because of decreased gastrointestinal 
absorption and increased iron loss, and is not indicated dur-
ing flare-up of inflammatory bowel diseases.6–9 As a result, 
intravenous (IV) iron formulations have been approved in 
over 50 countries, including Switzerland, to correct iron 
deficiency among primary care patients. IV formulations may 
be indicated, for example, if oral therapy does not bring the 
expected results despite good compliance or is not tolerated 
by the patient.10–14
Increased use of IV iron has been reported in  Switzerland15 
despite the lack of large-scale, good quality studies exam-
ining the effectiveness of oral and/or IV treatment for iron 
deficiency without anemia.16 Most studies assessing the 
effectiveness of IV versus oral iron treatment were conducted 
in specific populations, such as patients with chronic renal 
insufficiency, inflammatory diseases, neoplastic diseases, 
during or after pregnancy, but not among primary care 
patients.17–21 In addition, hypersensitivity reactions after iron 
infusion are not negligible and can be life threatening. Tran-
sient decreases in serum phosphate below the normal range 
are frequent. Although these are generally asymptomatic, the 
long-term consequences of repeated iron infusions on bone 
metabolism are not known.22
Several countries have developed initiatives to promote 
the appropriate and efficient use of the relevant tests and 
procedures.23–26 Since it is the mission of training institutions 
to ensure both the most rational use of medical resources 
and a high quality of patient care, we decided to conduct a 
quality improvement project on the use of oral and IV iron 
substitution in a division of primary care. The aim of the 
project was to evaluate whether iron deficiency has been 
managed appropriately in clinical practice 5 years after the 
commercialization of ferric carboxymaltose in Switzerland.
Methods
Study design and setting
A retrospective observational study was conducted in the 
Division of Primary Care at the Geneva University Hos-
pitals, Switzerland. The mission of this division includes 
delivering primary medical care to patients, providing pre- 
and postgraduate training in primary care, and conducting 
research in community-based clinics in Geneva, which is a 
canton of 450,000 inhabitants. The division is spread out 
over seven geographically distinct medical sites over the 
city but most clinical activities are conducted in the general 
outpatient clinic at the University Hospital. Each year, the 
clinic provides 13,000 scheduled medical consultations. It 
also trains 22 medical residents in ambulatory care. The 
patient catchment includes the general population of Geneva, 
particularly the socioeconomically deprived sector, including 
many vulnerable legal and illegal immigrants.
Selection of study subjects
All patients treated for iron deficiency in this clinic in 
March and April 2012 were included, excepting those with 
a hemoglobin level inferior to 80 g/L or a renal clearance 
inferior to 30 mL/min. According to our laboratory values, 
iron deficiency anemia was defined as a hemoglobin level 
of <120 g/L for females and <130 g/L for males, with a fer-
ritin level of <100 μg/L. Ferritin reference values for of iron 
deficiency vary according to sex, age, and the presence of 
several chronic conditions (12 and 200 μg/L) and a recent 
review suggested to consider serum ferritin <100 μg/L as an 
indicator of iron deficiency for most conditions.8 However, it 
is usually agreed that serum ferritin <10–15 μg/L represents 
exhausted reserves and that ferritin <30 μg/L indicates iron 
deficiency for patients without coexistent inflammatory 
disease.27
Measurement and outcomes
Subjects were identified by reviewing all computerized medi-
cal files of patients who had visited the general outpatient 
clinic during March and April 2012 and had a documented 
iron supplementation prescribed. Nurses’ records were also 
reviewed for identification of patients who had received IV 
iron. A team of two residents and three chief residents devel-
oped a grid to analyze the relevant medical files and collect 
the following data: sociodemographic characteristics; iron, 
ferritin, and C-reactive protein levels; documented rationale 
for measuring iron levels (or presumed rationales according to 
symptoms or risk factors documented); suspected underlying 
etiology of iron deficiency (or presumed etiology according 
to the complementary investigations that were requested); 
treatment schedule; rationale for IV treatment; and, finally, the 
planned clinical and biological follow-up. This chart was first 
tested on ten medical files to evaluate the clarity and consis-
tency of the topics and refine the rules of coding accordingly.
We reviewed the literature on iron deficiency detection 
and management and developed an algorithm based on results 
of scientific studies and national recommendations.2,3,13,20,28–32 
At the end of our study, we distributed this algorithm into 
our Division of Primary Care medicine in order to optimize 
our medical practices (Figure 1).




Iron deficiency and substitution practices
Indication for blood transfusion?
Indication for intravenous treatment?10,30,32
• Hb <70 g/L  
• CRD (CrClr <30 mL/min)
• Flare-up of inflammatory bowel disease
• Malabsorption syndrome (including bypass)
• Optimal administration
  (3 months, mornings with vitamin C)
• Clinical follow-up
• Hb <80 g/L if >65 years, CVD, pulmonary
  disease








• Compliance (duration, vitamin C)
• Treatment of underlying pathology
• Etiological diagnostic differential
• Prescription related problem
• Persistence of mild iron deficiency
   or anemia
• Mild side effects (change of product)
• Symptoms associated with iron deficiency
and/or anemia: fatigue, hair loss, nail disorders,
tachycardia, dyspnea, decreased cognitive
performance, irritability, apathy, depression,
reduced physical endurance, restless leg
syndrome, and alopecia3,28,29,33,34
• Risk factors for iron deficiency: low intake, 
malabsorption, blood loss, and increased
needs (eg, pregnancy)2
Iron and Hb measurements




Repeat oral treatment if:
• Biological follow-up 15 days after end
  of oral treatment
Failure?
Blood transfusion (1 BU =250 mg iron,
increases Hb 10 g/L)
+ iron treatment
IV iron treatment:
• Presence of iron deficiency without 
  anemia: iron reserve replacement
  (=500 mg if weight >35 kg) or 1,000 mg if 
  ferritine <10 µg/L
• Presence of anemia: Body weight
  (kg) × (Hb goal – Hb measured) (g/dL) ×
  2,4+ iron reserve replacement
  (=500 mg if weight >35 kg)31
• Biological follow-up 8 weeks after end
  of IV treatment
• Persistence or worsening of anemia 
  despite appropriate treatment
• Severe side effects with oral treatment
Clinical and biological follow-up if etiology
persists.
Second-line IV treatment if:10–12
Figure 1 Algorithm for iron deficiency management.
Note: Developed in collaboration with Dr Favrat (Policlinique médicale universitaire, CHUV) and Dr Sami (Service of Hematology, HUG).
Abbreviations: Hb, hemoglobin; Ht, hematocrit; MCV, mean corpuscular volume; MCHC, mean corpuscular hemoglobin concentration; CRP, C-reactive protein; creat, 
creatinine; ALAT, aspartate transaminase; CVD, cardiovascular disease; BU, blood unit; CRD, chronic renal disease; IV, intravenous.





Table 3 Clinical and biological follow-up of patients with iron 
deficiency
Follow-up Planned Performed
n (%) n (%)
Iron oral treatment
Clinical follow-up 63 (78.8) 52 (65.0)
Ferritin 52 (65.0) 43 (53.8)
Hemoglobin 48 (60.0) 39 (48.8)
Iron intravenous treatment
Clinical follow-up 23 (82.1) 14 (50.0)
Ferritin 19 (67.9) 12 (49.9)
Hemoglobin 19 (67.9) 14 (50.0)
The approval of the Research Ethics Committee of the 
Geneva University Hospitals and patient consent was not 
sought because the study was deemed an improvement 
 activity and not a human subject research.
Statistical analysis
Participants’ sociodemographic data, ferritin levels and 
documented rationale for measuring iron levels, suspected 
etiologies, treatment schedule, reasons for choosing IV 
treatment, and planned clinical and biological follow-up 
were analyzed descriptively using mean and/or percentages. 
SPSS software Version 18 (SPSS Inc., Chicago, IL, USA) 
was used for the analysis.
Results
Out of 1,671 patients seen in March and April 2012, 97 
patients were initially identified. Four patients met the 
exclusion criteria and so 93 patients were included in the 
study: 86 females and seven males. Median age was 40.2 
years (standard deviation 11.8 years). In all, 81.7% (n=81) 
of the prescribers were residents and 12.9% (n=12) senior 
residents or attending physicians. Ferritin was measured in 
97% (n=90) of patients and its mean value was 17.2 μg/L 
(standard deviation 13.3 μg/L).
The rationale for measuring iron levels was documented 
in 81.7% (n=76) medical files. The rationale for measuring 
C-reactive protein levels was documented in 30.1% (n=28) 
of medical files. The main reasons included presence of 
symptoms associated with iron deficiency, such as fatigue, 
or presence of risk factors for iron deficiency (mainly gyne-
cological blood loss) (Table 1). The suspected etiology for 
iron deficiency was documented in 66.7% (n=62) of all cases. 
Gynecological and digestive blood losses were the main 
suspected causes. Malabsorption or low iron intakes were 
mentioned to a lesser extent (Table 1).
The majority of patients received an oral treatment (Table 2). 
Out of 28 patients treated with IV iron, only seven received it 
as first-line and 21 as second-line treatment. The rationale for 
using IV iron as first-line treatment was documented in half 
of the cases: malabsorption (one), noncompliance (one), very 
low ferritin (7 μg/L) (one), and low hemoglobin (86 g/L) (one). 
When IV iron was used as a second-line treatment, the rationale 
was mentioned in 95% (n=20) of the cases: persistence of iron 
deficiency despite oral treatment correctly taken (n=14; 70%) 
and/or adverse effects of oral treatment (n=7; 35%).
Clinical and biological follow-up at 3 months was planned 
in more than two-thirds of the patients but not all took place 
(Table 3).
Table 1 Documented reasons for measuring iron levels and 
suspected etiologies of iron deficiency
Documentation in medical files N (%)
Reasons for measuring iron levels 76 (81.7)
Fatigue 33 (43.4)
Concentration difficulties 5 (6.6)
Dyspnea 4 (5.3)
Irritability 3 (3.9)
Cutaneous and nail disorders 7 (9.2)
Gastrointestinal blood loss 5 (6.6)
Gynecological blood loss 3 (3.9)
Malabsorption 3 (3.9)
Low iron intake 2 (2.6)
Routine check-up 5 (6.6)
Suspected etiology of iron deficiency 62 (66.7)
Gastrointestinal blood loss 38 (31.4)
Gynecological blood loss 55 (45.5)
Blood donation 1 (0.8)
Malabsorption 8 (6.6)
Low iron intake 10 (8.3)
Table 2 Frequency of use and documented reasons for oral or 
intravenous (IV) iron treatment
Treatment n (%)
Frequency of treatment
Oral treatment 65 (69.9)
Oral and IV treatment 15 (16.1)
First-line IV treatment 7 (7.5)
Second-line IV treatment 21 (22.6)
IV treatment 13 (14.0)
Documented reasons for IV treatment
First-line IV treatment 4 (57.1)
Second-line IV treatment 20 (95.2)
Discussion
The study shows that there was no clear overutilization of 
IV iron substitution in an academic division of primary care 
medicine 5 years after the approval of ferric carboxylmaltose 
for treatment of iron deficiency in Switzerland. Residents 
generally prescribed oral iron in first-line treatment of iron 
deficiency. However, several steps of the iron deficiency 
management were not optimally documented.




Iron deficiency and substitution practices
Residents did not systematically note the rationale for 
checking iron levels. Iron deficiency screening has not 
been proven to be useful as a routine procedure. Iron status 
should generally be requested in the presence of suggestive 
symptoms, such as fatigue, faintness, weakness, hair loss, 
loss of concentration, reduced physical endurance, and rest-
less leg syndrome in females of childbearing age.3,5,28,29,33,34 
It should also be determined in the presence of risk factors 
of iron deficiency, such as low dietary iron (vegetarian diet, 
socioeconomic difficulty), particularly during growth and 
pregnancy; diseases that impair iron absorption; gastroin-
testinal loss (chronic inflammatory disease, celiac disease, 
and cancer); gynecological or urological loss; renal or 
cardiac insufficiency; regular blood donations; and recent 
surgery.2,35,36
Documentation of the suspected etiology was made in 
approximately two-thirds of medical files. The main risk 
factor for iron deficiency is low intake when iron require-
ments are especially high. However, more chronic and severe 
illnesses, such as gastrointestinal blood loss from an ulcer, 
carcinoma, or inflammatory bowel disease, or a uterine 
fibroma, for example, can be misdiagnosed and thus lead to 
poor therapeutic management.5,15,35–37
According to Swiss recommendations,13 there was no 
clear overutilization of IV iron substitution as a first-line 
treatment. The majority of IV iron substitution was prescribed 
as a second-line treatment after a documented oral treatment 
failure or intolerance. However, the indication of first-line 
IV therapy was documented in only half of cases, suggesting 
that the rationale of IV treatment may not always be based on 
evidence. It is noted that a few studies show that IV formula-
tions are more effective than oral forms in presence of iron 
deficiency from both biological and clinical perspectives (bet-
ter physical or cognitive performances, decreased symptoms, 
decreased need for transfusions or erythropoietin).15,21,36,38,39 
However, oral iron substitution is still considered to be an 
economic and effective way to treat iron deficiency if it is 
taken appropriately over several months and early treatment 
is implemented before total exhaustion of reserves.8
Finally, 70% of second-line IV therapy was prescribed for 
persistent iron deficiency attributed to the ineffectiveness or 
intolerance of oral treatment. Given the length of oral treat-
ment and frequency of side effects, the persistence of an iron 
deficiency could be due to poor compliance not disclosed by 
the patient or a suboptimal oral intake (eg, not taken while 
fasting or combined with ascorbic acid). In case of intoler-
ance, a change of formulation of oral iron  substitution or time 
of dosing may be an appropriate strategy before considering 
IV treatment.
Physicians may also be put under pressure by patients’ 
demands for a quick IV treatment. As with the use of IV 
or intramuscular analgesia in case of acute pain, it may be 
easier to meet the demands of patients to have an IV treat-
ment, rather than to persuade them that it is not needed or 
does not bring any additional benefit. Technological progress 
brings more and more opportunities for interventions which 
quickly become “state of the art” without any evidence of 
true superiority.26
Limitations
There are several limitations to this study. First, it is descrip-
tive and retrospective, not an interventional study. Therefore, 
we do not know whether the guidelines created and distrib-
uted after this work improved residents’ documentation and 
management practices of iron deficiency. Second, we based 
our analysis on a review of medical files and therefore relied 
on documented data to assess whether clinical reasoning and 
practice patterns were correct. There were indeed several 
missing data on oral treatment noncompliance or rationale 
for second-line treatment. It is possible that some residents 
may have had correct clinical reasoning regarding measuring 
iron levels and subsequent management but omitted to docu-
ment them sufficiently. Finally, because the study took place 
only in one clinical setting, our results may not be applicable 
to other outpatient settings. They may not be relevant for 
countries where IV iron supplementation for iron deficiency 
without anemia is neither common nor recommended, 
for example.
Conclusion
This study shows that in a country where IV iron substitution 
is recommended as a second-line treatment for iron deficiency 
without anemia, there was no clear overuse of it in an aca-
demic primary care division. However, several steps of iron 
deficiency management were not appropriately documented, 
suggesting lack of knowledge or clinical reasoning shortcuts 
that may lead to misdiagnoses of chronic diseases. More 
training is required in this field.
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